CHENYSEServices-Home Health Care ServicesFiscal year ends December 31
CHEMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$508.29−4.09 (-0.80%)
Close on Oct 19, 2026
- Market cap
- $6.71B
- P/E (TTM)
- 25.5
- Dividend yield
- 0.43%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
32.5%−1.2 pts over 5 years
Operating margin
13.4%−5.4 pts over 5 years
Net margin
10.5%−4.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.1% | +5.8% | +4.0% | +5.1% | |
| Gross profit | -3.6% | +2.5% | +3.3% | +6.1% | |
| Operating income | -7.7% | -0.5% | -2.8% | +6.3% | |
| Net income | -12.2% | +2.0% | -3.7% | +9.2% | |
| EPS, diluted | -7.8% | +3.5% | -1.2% | +11.2% | |
| Free cash flow | -11.5% | +8.8% | -5.4% | +9.8% | |
| Dividend per share | +22.2% | +14.1% | +10.8% | +9.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 21.0% | 39.3% | 25.3% | |
| Return on assets | 12.6% | 23.6% | 16.5% | |
| Current ratio | 0.99 | 1.10 | 1.05 | |
| Debt to equity | 0.21 | – | – | |
| Net debt to EBITDA | 0.44× | – | – | |
| Interest coverage | 48.1× | 165.5× | 193.3× | |
| Inventory turnover | 184.8× | 189.4× | 216.9× | |
| Capex to revenue | 2.5% | 2.8% | 2.5% | |
| Diluted shares | 17M | 16M | 14M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Chemed generated $1.75B from operations and spent $1.96B on capital expenditure, dividends and share buybacks. 15% of that went back into the business.
Generated
$1.75B
Used
$1.96B
Capital expenditure$285.18M15%Dividends$126.32M6%Share buybacks$1.55B79%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin10.5%
×Asset turnover1.58×
×Equity multiplier1.53×
=Return on equity, FY202525.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 10.5% | 1.58× | 1.53× | 25.3% |
| FY2024 | 12.4% | 1.46× | 1.50× | 27.1% |
| FY2023 | 12.0% | 1.46× | 1.63× | 28.6% |
| FY2022 | 11.7% | 1.53× | 1.96× | 35.1% |
| FY2021 | 12.6% | 1.54× | 1.82× | 35.2% |
| FY2020 | 15.4% | 1.54× | 1.66× | 39.3% |
| FY2019 | 11.3% | 1.73× | 1.70× | 33.4% |
| FY2018 | 11.5% | 1.88× | 1.67× | 36.3% |
| FY2017 | 5.9% | 1.85× | 1.69× | 18.4% |
| FY2016 | 6.9% | 1.82× | 1.67× | 21.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$265.24M
- Cash generatingOperating cash flow above zero$388.27M
- Return on assets improvedROA up on the prior year18.1% → 15.9%
- Earnings backed by cashOperating cash flow above net income$388.27M vs $265.24M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.38 → 1.05
- No dilutionShare count did not rise15M → 14M
- Gross margin improvedGross margin up on the prior year35.14% → 32.54%
- More efficientAsset turnover rose1.46 → 1.52